title: Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.
abstract: A series of in vivo and in vitro assays were conducted to characterize the pharmacological effects of the first generation abused synthetic cannabinoid CP47,497, a racemic bicyclic cannabinoid that is similar in structure to the potent, high-efficacy synthetic cannabinoid CP55,940. CP47,497 was less efficacious than CP55,940 in activating G-proteins and dose-dependently produced common CB1 receptor-dependent pharmacological effects (i.e. catalepsy, hypothermia, antinociception, and hypolocomotion). CP47,497 also substituted for Δ9-tetrahydrocannabinol (THC) in the mouse drug discrimination, indicating that both drugs elicited a similar interceptive stimulus. The pharmacological effects of CP47,497 underwent tolerance following repeated administration and showed cross-tolerance following repeated THC administration, further suggesting a common cannabimimetic mechanism of action. Finally, the CB1 receptor antagonist rimonabant precipitated similar magnitudes of somatic withdrawal responses in mice treated repeatedly with THC or CP47,497. Taken together, these data verify the acute cannabimimetic effects of CP47,497, and indicate tolerance and dependence following repeated administration. The assays used here provide a straightforward approach to characterize the emerging next generation of abused synthetic cannabinoids.
authors.forename: Travis W
authors.initials: TW
authors.lastname: Grim
authors.forename: Kimberly L
authors.initials: KL
authors.lastname: Samano
authors.forename: Bogna
authors.initials: B
authors.lastname: Ignatowska-Jankowska
authors.forename: Qing
authors.initials: Q
authors.lastname: Tao
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Sim-Selly
authors.forename: Dana E
authors.initials: DE
authors.lastname: Selley
authors.forename: Laura E
authors.initials: LE
authors.lastname: Wise
authors.forename: Alphonse
authors.initials: A
authors.lastname: Poklis
authors.forename: Aron H
authors.initials: AH
authors.lastname: Lichtman
mesh_terms: D000818:Animals; D063387:Cannabinoid Receptor Antagonists / Q000494:pharmacology; D002186:Cannabinoids / Q000494:pharmacology*; D013759:Dronabinol / Q000494:pharmacology; D004361:Drug Tolerance; D063388:Endocannabinoids / Q000494:pharmacology; D005260:Female; D019204:GTP-Binding Proteins / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D000077285:Rimonabant
chemical_list: D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids; D063388:Endocannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D013759:Dronabinol; D019204:GTP-Binding Proteins; D000077285:Rimonabant